Drugs / PF-03814735
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00424632 | Nov 2006 → Jun 2009 | cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-03814735 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00424632 ↗ |
| Known as | PF 3814735 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4289017 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL4289017 ↗2“Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL4289017 ↗ “the aurora kinase A and B inhibitor, PF-03814735” PMID 21852114 ↗ Aug 2011 |
| Modality | Small molecule | — CHEMBL4289017 ↗ |
| Route | Oral | “Patients with advanced solid tumours received oral, once-daily (QD) PF-03814735” PMID 21852114 ↗ Aug 2011 |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL4289017 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL4289017 ↗ |